Avenue Therapeutics (ATXI) 10-K 18 Mar 24 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 01, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0001644963
Entity Registrant Name	AVENUE THERAPEUTICS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-38114
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-4113275
Entity Address, Address Line One	1111 Kane Concourse, Suite 301
Entity Address, City or Town	Bay Harbor Islands
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33154
City Area Code	781
Local Phone Number	652-4500
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	ATXI
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 8,522,013
Entity Common Stock, Shares Outstanding		44,260,667
Auditor Name	KPMG LLP
Auditor Location	New York, NY
Auditor Firm ID	185

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,783	$ 6,708
Prepaid expenses and other current assets	67	137
Total assets	1,850	6,845
Current liabilities:
Warrant liability	586	2,609
Total current liabilities	1,196	3,579
Total liabilities	1,196	3,579
Commitments and Contingencies (Note 6)
Stockholders’ equity
Preferred stock ($0.0001 par value), 2,000,000 shares authorized	0	0
Common shares, 75,000,000 shares authorized and 25,597,622 shares issued and outstanding as of December 31, 2023; and 20,000,000 shares authorized and 4,773,841 shares issued and outstanding as of December 31, 2022	3	0
Additional paid-in capital	92,507	84,456
Accumulated deficit	(90,928)	(80,551)
Total stockholders’ equity attributed to the Company	1,582	3,905
Non-controlling interests	(928)	(639)
Total stockholders’ equity	654	3,266
Total liabilities and stockholders’ equity	1,850	6,845
Nonrelated Party [Member]
Current liabilities:
Accounts payable and accrued expenses	287	949
Related Party [Member]
Current liabilities:
Accounts payable and accrued expenses	$ 323	$ 21

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Preferred Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred Stock, shares issued (in shares)	250,000	250,000
Preferred Stock, shares outstanding (in shares)	250,000	250,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized (in shares)	75,000,000	20,000,000
Common Stock, Shares, Issued (in shares)	25,597,622	4,773,841
Common Stock, Shares, Outstanding (in shares)	25,597,622	4,773,841

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 6,131	$ 2,698
Research and development - licenses acquired	4,230	0
General and administrative	4,179	5,345
Loss from operations	(14,540)	(8,043)
Interest income	(126)	(20)
Financing costs – warrant liabilities	(332)	(1,160)
Change in fair value of warrant liabilities	4,258	5,580
Net loss	(10,488)	(3,603)
Net loss attributable to non-controlling interest	(111)	(51)
Net loss attributable to common stockholders	$ (10,377)	$ (3,552)
Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.98)	$ (1.63)
Weighted average number of common shares outstanding, basic and diluted (in shares)	10,591,636	2,185,159

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Private Placement [Member] Preferred Stock [Member] Preferred Class A [Member]	Private Placement [Member] Common Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member] Retained Earnings [Member]	Private Placement [Member] Noncontrolling Interest [Member]	Private Placement [Member]	Preferred Stock [Member] Preferred Class A [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2021							250,000	1,405,959
Balance at Dec. 31, 2021							$ 0	$ 0	$ 80,450	$ (76,999)	$ 0	$ 3,451
Share based compensation (in shares)							0	75,505
Share based compensation							$ 0	$ 0	649	0	0	649
Common shares issuable - Founders Agreement							$ 0	$ 0	526	0	0	526
Issuance of common shares and pre-funded warrants at private placement, net of issuance costs (in shares)							0	3,636,365
Issuance of common shares and pre-funded warrants at private placement, net of issuance costs							$ 0	$ 0	3,205	0	0	3,205
Repurchase of common stock held by InvaGen (in shares)							0	(388,888)
Repurchase of common stock held by InvaGen							$ 0	$ 0	(1,104)	0	0	(1,104)
Fortress contribution of Baergic Inc							0	0	(99)	0	0	(99)
Issuance of subsidiaries’ common shares for license expenses							$ 0	$ 0	4	0	0	4
Exercise of warrants (in shares)							0	44,900
Exercise of warrants							$ 0	$ 0	237	0	0	237
Non-controlling interest in subsidiaries							0	0	588	0	(588)	0
Net loss attributable to non-controlling interest							0	0	0	0	(51)	(51)
Net loss attributable to common stockholders							$ 0	$ 0	0	(3,552)	0	(3,552)
Balance (in shares) at Dec. 31, 2022							250,000	4,773,841
Balance at Dec. 31, 2022							$ 0	$ 0	84,456	(80,551)	(639)	3,266
Share based compensation (in shares)							0	0
Share based compensation							$ 0	$ 0	906	0	0	906
Common shares issuable - Founders Agreement							0	0	371	0	0	371
Issuance of common shares and pre-funded warrants at private placement, net of issuance costs							0	1	865	0	0	866
Issuance of subsidiaries’ common shares for license expenses							$ 0	$ 0	6	0	0	6
Exercise of warrants (in shares)							0	14,272,382
Exercise of warrants							$ 0	$ 1	0	0	0	1
Net loss attributable to non-controlling interest							0	0	0	0	(111)	(111)
Net loss attributable to common stockholders							$ 0	$ 0	0	(10,377)	0	(10,377)
Balance (in shares) at Dec. 31, 2023							250,000	25,597,622
Balance at Dec. 31, 2023							$ 0	$ 3	92,507	(90,928)	(928)	654
Issuance of common stock to Fortress (in shares)							0	374,644
Issuance of common stock to Fortress							$ 0	$ 0	72	0	0	72
Issuance of common stock and pre-funded warrants, net of offering costs - November 2023 public offering (in shares)							0	3,853,400
Issuance of common stock and pre-funded warrants, net of offering costs - November 2023 public offering							$ 0	$ 1	3,873	0	0	3,874
Issuance of common stock and pre-funded warrants, net of offering costs - registered direct offering and private placement (in shares)							0	448,000
Issuance of common stock for license expense (in shares)							0	1,108,270
Issuance of common stock for license expense							$ 0	$ 0	1,230	0	0	1,230
Shares issued in a private placement offering (in shares)	0	767,085
Shares issued in a private placement offering	$ 0	$ 0	$ 550	$ 0	$ 0	$ 550
Noncontrolling Interest, Decrease from Deconsolidation							$ 0	$ 0	$ 178	$ 0	$ (178)	$ 0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (10,488)	$ (3,603)
Reconciliation of net loss to net cash used in operating activities:
Share based compensation	906	649
Change in fair value of warrant liability	(4,258)	(5,580)
Issuance of Stock Under Founders Agreement	371	526
Common Stock, Issued to Fortress, Value	72	0
Issuance of Stock for Licenses Acquired	1,230	0
Research and Development License, Acquired Expense	3,000	0
License Expenses Paid In Kind	6	4
Changes in operating assets and liabilities:
Other receivables - related party	0	90
Prepaid expenses and other current assets	70	(30)
Net cash and cash equivalents used in operating activities	(9,451)	(7,596)
Cash flows from investing activities:
Purchase of research and development licenses	(3,000)	0
Net cash used in investing activities	(3,000)	0
Cash flows from financing activities:
Proceeds from issuance of common stock, warrants, and pre-funded warrants, net of issuance costs	7,525	11,497
Repurchase of common stock held by InvaGen	0	(1,104)
Proceeds from exercise of warrants	1	148
Net cash provided by financing activities	7,526	10,541
Net change in cash and cash equivalents	(4,925)	2,945
Cash and cash equivalents, beginning of period	6,708	3,763
Cash and cash equivalents, end of period	1,783	6,708
Supplement disclosure of non-cash information:
Receipt of interest in Baergic from Fortress	0	99
Unpaid offering costs	0	14
Related Party [Member]
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	(662)	385
Nonrelated Party [Member]
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	$ 302	$ (37)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2023
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		9B. Other Information During the three December 31, 2023, none 16a 1 1934, 10b5 1 10b5 1 408 1933 ​ ​
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 1 - Organization, Plan of

Note 1 - Organization, Plan of Business Operations	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 Organization, Plan of Business Operations Avenue Therapeutics, Inc. (the “Company” or “Avenue”) was incorporated in Delaware on February 9, 2015, 2017. AJ201 101 Baergic On May 11, 2022, March 9, 2017, March 9, 2017. 2019 The transaction expanded Avenue’s development portfolio within neuroscience. Evaluation and negotiation of the Contribution Agreement was overseen, and execution of the Contribution Agreement was approved, by special committees at the Avenue and Fortress levels, both of which exclusively comprised independent and disinterested directors of the respective companies’ boards. See Note 4 AJ201 On February 28, 2023, JM17, Nrf1 Nrf2, AJ201, 1b/2a AJ201 AJ201 AJ201 Reverse Stock Split On September 23, 2022, 1 15 one No one September 22, 2022, On February 2, 2023, 2022 All share and per share information has been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented, unless otherwise indicated. Stock Purchase and Merger Agreement In July 2022 October 2022, December 31, 2022 seven 2023 2022, Liquidity and Capital Resources October 2022 In October 2022, “October 2022 “October 2022 “October 2022 October 2022 “October 2022 “October 2022 “October 2022 October 2022 “October 2022 “October 2022 October 2022 October 2022 October 2022 October 2022 The October 2022 five October 2022 October 2022 October 2022 45 October 2022 October 2022 October 2022 October 2022 October 2022 October 2022 October 2022 October 2022 October 2022 October 2022 October 2022 October 11, 2022. October 2022 October 2022 October 2022 The Company received net proceeds from the October 2022 January 2023 On January 27, 2023, “January 2023 January 2023 “January 2023 January 2023 January 2023 “January 2023 January 2023 December 31, 2023, January 2023 January 2023 On January 27, 2023, “January 2023 “January 2023 “January 2023 January 2023 January 2023 January 2023 one January 2023 January 2023 three January 2023 January 2023 January 31, 2023, January 2023 The Company received net proceeds from the January 2023 In connection with the January 2023 “January 2023 1 April 2023, May 2023. 10 January 2023 January 2023 January 2024. September 2023 On September 8, 2023, “September 2023 “September 2023 “September 2023 1933, September 7, 2023, 5365 September 2023 not September 2023 In connection with the September 2023 September 8, 2024 ( “September 2023 “September 2023 September 2023 November 2023 On October 31, 2023, “November 2023 “November 2023 “November 2023 “November 2023 “November 2023 November 2023 “November 2023 “November 2023 November 2023 “November 2023 November 2023 “November 2023 November 2023 November 2023 “November 2023 November 2023 November 2023 November 2023 November 2023 “November 2023 November 2023 November 2023 November 2023 October 31, 2023 ( “November 2023 November 2023 November 2023 November 2023 November 2023 November 2023 November 2023 December 31, 2023, November 2023 November 2023 The November 2023 five November 2023 November 2023 November 2023 November 2023 November 2023 November 2023 November 2023 November 2, 2023. November 2023 November 2023 November 2023 November 2023 The Company received net proceeds from the November 2023 November 2023 10, November 2023 November 2023 January 2024. Going Concern These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. However, as described below, substantial doubt about the Company’s ability to continue as a going concern exists. The Company is not may December 31, 2023 1b/2a AJ201, 3 12 one not may

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2 Significant Accounting Policies Basis of Presentation & Principles of Consolidation The Company’s consolidated financial statements have been prepared in conformity with U.S. GAAP, include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented and are stated in U.S. dollars. The Company’s consolidated financial statements include the accounts of the Company and the accounts of the Company’s subsidiary. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements include the accounts of the Company’s subsidiary, Baergic. Because the Company owns less than 100% may Segments Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company views its operations and manages its business in one operating and reporting segment. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three December 31, 2023 2022 may December 31, 2023 not not may no Accounts Payable and Accrued Expenses Related Party In the normal course of business, Fortress pays for certain expenses on behalf of the Company. Such expenses are recorded as accounts payable and accrued expenses – related party and are recorded at the invoiced amount and reimbursed to Fortress in the normal course of business. Research and Development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third third Costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not no no Contingencies The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not Warrant Liability The Company has issued freestanding warrants to purchase shares of its common stock in connection with financing activities (Warrants as described in Note 8 Fair Value Measurements The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one three Level 1: Level 2: 1 Level 3: no The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not Annual Stock Dividend In September 2016, February 16 ( February 17 June 13, 2018, December 31 January 1 November 12, 2018 4 October 31, 2022, Pursuant to the Third Amended and Restated Certificate of Incorporation, the Company issued 1,685,767 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of the Company, on January 2, 2024. December 31, 2023 December 31, 2023 January 1, 2023. December 31, 2022, December 31, 2022. Stock-Based Compensation The Company expenses stock-based compensation to its employees, consultants and board members over the requisite service period based on the estimated grant-date fair value of the awards. The Company estimates the fair value of option grants using the Black-Scholes option pricing model, which includes assumptions for expected volatility, risk-free interest rate, dividend yield, and estimated expected term. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting tranche of the award. The Company accounts for forfeitures as they occur by reversing any expense recognized for unvested awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Stock options granted to employees generally fully vest over four ten Income Taxes The Company accounts for income taxes under ASC 740, Income Taxes 740” 740 740 not not ASC 740 not 740 no 2019 2021 not The Company’s policy for recording interest and penalties associated with audits is to record such expense as a component of income tax expense. There were no amounts accrued for penalties or interest as of or during the years ended December 31, 2023 2022 Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third Comprehensive Loss The Company’s comprehensive loss is equal to its net loss for all periods presented. Net Loss Per Share Loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding, excluding unvested restricted stock and stock options and preferred shares, during the period. Dividends declared are paid and set aside among the holders of shares of common stock and Class A Preferred stock pro-rata on an as-if-converted basis. The following table sets forth the potential common shares that could potentially dilute basic income per share in the future that were not For the Years Ended December 31, 2023 2022 Unvested restricted stock units/awards 98,137 13,137 Common stock issuable 2,101,495 322,225 Warrants 39,344,932 4,137,916 Options 1,685,000 — Class A Preferred stock 16,666 16,666 Total potential dilutive effect 43,246,230 4,489,944 Recent Accounting Pronouncement to be Adopted In October 2023, 2023 06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Updated and Simplification Initiative" 2023 06 August 2018 not June 30, 2027, not not not In November 2023, No. 2023 07, Segment Reporting (Topic 280 2023 07 280 one December 15, 2023, December 15, 2024. In December 2023, 2023 09, Income Taxes (Topic 740 December 15, 2024.

Note 3 - License Supplier Agree

Note 3 - License Supplier Agreement	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
License Agreement Disclosure [Text Block]	Note 3 License/Supplier Agreements IV Tramadol License Effective as of February 17, 2015, June 17, 2015, December 2019, On October 29, 2018, eight five Baergic Licenses In December 2019, two 2 3 α2,3 Development milestones totaling approximately $81.5 million in the aggregate are due upon achievement of such milestones. Commercial and sales-based milestone payments totaling approximately $151 million are due upon achievement of such milestones, as well as royalty payments in the low to high single digits on any future aggregate, annual, worldwide net sales. AnnJi License On February 28, 2023, AJ201 April 27, 2023 September 8, 2023. 1b/2a first The license provided under the AnnJi License Agreement is exclusive as to all oral forms of AJ201 AJ201 AJ201 In connection with the signing of the AnnJi License Agreement, the Company issued 831,618 shares of its common stock to AnnJi (“First Tranche Shares”) at a fair value of $0.9 million on March 30, 2023. September 26, 2023 eighth 1b/2a February 28, 2023, In connection with execution of the AnnJi License Agreement, Avenue entered into a registration rights agreement with AnnJi, pursuant to which Avenue filed a registration statement to register the resale of the First Tranche Shares and Second Tranche Shares issued to AnnJi. The Company filed such registration statement on Form S- 3 June 16, 2023, June 27, 2023.

Note 4 - Related Party Agreemen

Note 4 - Related Party Agreements	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 4 Related Party Agreements Founders Agreement and Management Services Agreement with Fortress Fortress entered into a Founders Agreement with Avenue in February 2015 2017. two one five 5 no two one four one ninety 90 one five 5x twelve 12 four one On September 13, 2016, one 7 Effective as of February 17, 2015, five five not 90 may not not first November 12, 2018, October 2022 Founders Agreement and Management Services Agreement with Baergic Pursuant to the Share Contribution Agreement between Avenue and Fortress, the Founders Agreement and Management Services Agreement that had previously been existing between Fortress and Baergic were assigned to Avenue, such that they now exist between Avenue and Baergic; those agreements are referred to herein as the Avenue-Baergic Founders Agreement and the Avenue-Baergic MSA, as applicable. The Annual Stock Dividend payable to the Company is 2.5% of common stock calculated as a percentage of fully diluted outstanding capital and became effective as of November 8, 2022. December 31, 2023 December 31, 2022, December 31, 2023 2022, December 31, 2023 2022 January 1, 2024 2023, The Avenue-Baergic Founders Agreement has an effective date of March 9, 2017, 15 one As additional consideration under the Avenue-Baergic Founders Agreement, Baergic will also: (i) pay an equity fee in shares of common stock, payable within five 5 no two one four one ninety 90 one five 5x twelve 12 four one The Avenue-Baergic MSA has an effective date of March 9, 2017, five five may not not no first Acquisition of Baergic On May 11, 2022, 1 The transaction was accounted for as an asset acquisition between entities under common control. As such, the transaction was recorded at carryover basis, with all assets, liabilities and non-controlling interests measured at their historical carrying values. The consolidated financial statements of the Company include the consolidated results of operations for Avenue and Baergic since the acquisition date on November 8, 2022.

Note 5 - Accounts Payable and A

Note 5 - Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 5 Accounts Payable and Accrued Expenses Accounts payable, accrued expenses and other liabilities consisted of the following (in thousands): As of December 31, 2023 2022 Accounts payable $ 78 $ 129 Accrued employee compensation 11 199 InvaGen contingent fee — 208 Accrued contracted services and other 198 413 Accounts payable and accrued expenses $ 287 $ 949

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 6 Commitments and Contingencies Leases The Company is not Litigation The Company recognizes a liability for a contingency when it is probable that liability has been incurred and when the amount of loss can be reasonably estimated. When a range of probable loss can be estimated, the Company accrues the most likely amount of such loss, and if such amount is not December 31, 2023 2022 no

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Equity [Text Block]	Note 7 Stockholders Equity Class A Preferred Stock On September 13, 2016, may one not On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Class A Preferred Stock shall be entitled to cast for each share of Class A Preferred Stock held by such holder as of the record date for determining stockholders entitled to vote on such matter, the number of votes that is equal to one one tenth 1.1 Each share of Class A Preferred Stock is convertible, at the option of the holder, into one not one September 2022, one Common Stock On January 30, 2023, 2022 December 31, 2023. December 31, 2022, Holders of the Company's common stock are entitled to one not may In the event of the Company's liquidation or dissolution, the holders of common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no may may Equity Incentive Plan The Company has in effect the Avenue Therapeutics, Inc. 2015 “2015 2015 January 2015 December 2021. 2015 January 30, 2023. 2015 no Total shares available for the issuance of stock-based awards under the Company’s 2015 December 31, 2023 Restricted Stock Units and Restricted Stock Awards The following table summarizes restricted stock unit and award activity for the year ended December 31, 2023 Number of Units and Awards Weighted Average Grant Date Fair Value Unvested balance at December 31, 2021 94,418 $ 56.25 Forfeited (666 ) 13.95 Vested (80,615 ) 40.83 Unvested balance at December 31, 2022 13,137 $ 12.17 Granted 85,000 1.14 Forfeited — — Vested — — Unvested balance at December 31, 2023 98,137 $ 12.17 For the years ended December 31, 2023 2022 At December 31, 2023 not December 31, 2023 Stock-Based Compensation The following table summarizes stock-based compensation expense for the years ended December 31, 2023 2022 For the year ended December 31, 2023 2022 Research and development $ 199 $ 297 General and administrative 707 352 Total stock-based compensation expense $ 906 $ 649 Stock Options The following table summarizes the stock option activity for the years ended December 31, 2023 2022 Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2021 — $ — $ — Outstanding as of December 31, 2022 — $ — $ — Granted 1,685,000 1.14 Outstanding as of December 31, 2023 1,685,000 $ 1.14 9.50 $ — Vested and Exercisable as of December 31, 2023 262,500 1.14 9.50 $ — The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of common stock for those options that had exercise prices lower than the fair value of common stock. Upon the exercise of stock options, the Company will issue new shares of its common stock. For the years ended December 31, 2023 2022 December 31, 2023, The Company used the Black-Scholes Model for determining the estimated fair value of stock-based compensation related to stock options. The table below summarized the assumptions used: For the Year Ended December 31, 2023 2022 Risk-free interest rate 4.14 % — Expected dividend yield — — Expected term in years 5.8 - 5.9 — Expected volatility 125.72 % — Stock Warrants The following table summarizes the warrant activity for the years ended December 31, 2023 2022 Warrants Weighted Average Exercise Price Aggregate Intrinsic Value (in thousands) Outstanding, December 31, 2021 997 $ 9.98 $ 11 Granted 5,166,119 $ 2.67 — Exercised (1,029,200 ) $ 0.14 — Outstanding, December 31, 2022 4,137,916 $ 1.55 $ 1 Granted 49,479,398 $ 0.26 — Exercised (14,272,382 ) $ 0.00 — Outstanding, December 31, 2023 39,344,932 $ 0.49 $ — Upon the exercise of warrants, the Company will issue new shares of its common stock.

Note 8 - Common Stock Warrant L

Note 8 - Common Stock Warrant Liabilities	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Common Stock Warrant Liabilities [Text Block]	Note 8 Common Stock Warrant Liabilities The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 815. 480, 480, 815, For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not Warrant Liability The Company has issued freestanding warrants to purchase shares of its common stock in connection with financing activities ( October 2022 January 2023 1 October 2022 January 2023 October 2022 October 2022 October 11, 2022 December 31, 2022. January 2023 January 31, 2023. The fair value of the warrants is re-measured at each financial reporting date with any changes in fair value being recognized in change in fair value of warrant liabilities, a component of other income (expense), in the consolidated statements of operations and comprehensive income (loss). The Company will continue to re-measure the fair value of the October 2022 October 10, 2027 January 2023 January 31, 2026. October 2022 one January 2023 October 2022 January 2023 October 2022 January 2023 December 31, 2023. Fair Value of Warrant Liabilities Warrant liabilities are categorized within Level 3 October 2022 January 2023 Warrants Warrants Total Fair value of warrants outstanding as of December 31, 2021 $ - $ — $ — Fair value of warrants at issuance as of October 11, 2022 8,278 — Exercise of warrants (89 ) — Change in fair value of warrants (5,580 ) — Fair value of warrants outstanding as of December 31, 2022 2,609 — 2,609 Fair value of warrants at issuance as of January 31, 2023 — 2,235 Change in fair value of warrants (2,183 ) (2,075 ) Fair value of warrants outstanding as of December 31, 2023 $ 426 $ 160 $ 586 The key inputs for the October 2022 December 31, December 31, 2023 2022 (Black-Scholes (Monte Carlo model) Simulation) Stock price $ 0.16 $ 1.16 Risk-free interest rate 3.84 % 4.02 % Expected dividend yield — — Expected term in years 3.78 4.78 Expected volatility 148 % 93 % The key inputs for the January 2023 December 31, January 31, 2023 2023 Stock price $ 0.16 $ 1.38 Risk-free interest rate 4.23 % 3.90 % Expected dividend yield — — Expected term in years 2.10 3.00 Expected volatility 175 % 160 %

Note 9 - Income Taxes

Note 9 - Income Taxes	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 9 Income Taxes The Company has accumulated net losses since inception and has not December 31, 2023 2022 A reconciliation of the statutory U.S. federal rate to the Company’s effective tax rate is as follows: For the years ended December 31, 2023 2022 Statutory federal income tax rate 21 % 21 % State taxes, net of federal tax benefit 11 % 10 % State rate change 1 % (1 )% Stock-based compensation 0 % (22 )% Other 0 % 3 % Credits 1 % 4 % None-deductible items (1 )% (11 )% Section 162(m) disallowance 0 % (3 )% Change in fair value of warrant liability 12 % 48 % Change in valuation allowance (45 )% (49 )% Income taxes provision (benefit) 0 % 0 % The components of the net deferred tax asset as of December 31, 2023 2022 As of December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 27,318 $ 25,660 Stock compensation and other 287 42 In process research and development 2,884 1,603 Accruals and reserves 4 64 Business interest expense disallowance — 122 Section 174 capitalization 2,253 622 Tax credits 2,926 2,859 Total deferred tax assets 35,672 30,972 Less valuation allowance (35,672 ) (30,972 ) Deferred tax assets, net of valuation allowance $ — $ — The Company has determined, based upon available evidence, that it is more likely than not not December 31, 2023 2022 As of December 31, 2023 not 2034 2034, not 2034. may 382 not 382 December 31, 2023 There are no 740, December 31, 2023 2022 not twelve Additionally, ASC 740 no December 31, 2023 2022 The federal and state tax returns for the years ended December 31, 2020 2021 2022 not

Note 10 - Subsequent Events

Note 10 - Subsequent Events	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	Note 10 Subsequent Events January 2024 On January 5, 2024, “January 2023 “January 2023 January 2023 January 31, 2023 ( “January 2023 “November 2023 January 2023 “November 2023 January 2023 November 2023 November 2, 2023 ( “November 2023 January 2023 January 2023 November 2023 January 2023 January 2023 November 2023 November 2023 x Nasdaq Hearing Panel Meeting On February 15, 2024, March 11, 2024, May 20, 2024 no Authorized Share Increase On January 9, 2024, February 20, 2024, Action by Written Consent of Stockholders to Effect Reverse Stock Split Effective March 6, 2024, 1 1 one 1.1 194.8 March 6, 2024. March 6, 2024

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation & Principles of Consolidation The Company’s consolidated financial statements have been prepared in conformity with U.S. GAAP, include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented and are stated in U.S. dollars. The Company’s consolidated financial statements include the accounts of the Company and the accounts of the Company’s subsidiary. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements include the accounts of the Company’s subsidiary, Baergic. Because the Company owns less than 100% may
Segment Reporting, Policy [Policy Text Block]	Segments Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company views its operations and manages its business in one operating and reporting segment.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three December 31, 2023 2022 may December 31, 2023 not not may no
Accounts Payable and Accrued Expenses [Policy Text Block ]	Accounts Payable and Accrued Expenses Related Party In the normal course of business, Fortress pays for certain expenses on behalf of the Company. Such expenses are recorded as accounts payable and accrued expenses – related party and are recorded at the invoiced amount and reimbursed to Fortress in the normal course of business.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third third Costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not no no
Commitments and Contingencies, Policy [Policy Text Block]	Contingencies The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not
Warrant Liability [Policy Text Block]	Warrant Liability The Company has issued freestanding warrants to purchase shares of its common stock in connection with financing activities (Warrants as described in Note 8
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one three Level 1: Level 2: 1 Level 3: no The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not
Stockholders' Equity, Policy [Policy Text Block]	Annual Stock Dividend In September 2016, February 16 ( February 17 June 13, 2018, December 31 January 1 November 12, 2018 4 October 31, 2022, Pursuant to the Third Amended and Restated Certificate of Incorporation, the Company issued 1,685,767 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of the Company, on January 2, 2024. December 31, 2023 December 31, 2023 January 1, 2023. December 31, 2022, December 31, 2022.
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company expenses stock-based compensation to its employees, consultants and board members over the requisite service period based on the estimated grant-date fair value of the awards. The Company estimates the fair value of option grants using the Black-Scholes option pricing model, which includes assumptions for expected volatility, risk-free interest rate, dividend yield, and estimated expected term. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting tranche of the award. The Company accounts for forfeitures as they occur by reversing any expense recognized for unvested awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Stock options granted to employees generally fully vest over four ten
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under ASC 740, Income Taxes 740” 740 740 not not ASC 740 not 740 no 2019 2021 not The Company’s policy for recording interest and penalties associated with audits is to record such expense as a component of income tax expense. There were no amounts accrued for penalties or interest as of or during the years ended December 31, 2023 2022
Noncontrolling Interests [Policy Text Block]	Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss The Company’s comprehensive loss is equal to its net loss for all periods presented.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding, excluding unvested restricted stock and stock options and preferred shares, during the period. Dividends declared are paid and set aside among the holders of shares of common stock and Class A Preferred stock pro-rata on an as-if-converted basis. The following table sets forth the potential common shares that could potentially dilute basic income per share in the future that were not For the Years Ended December 31, 2023 2022 Unvested restricted stock units/awards 98,137 13,137 Common stock issuable 2,101,495 322,225 Warrants 39,344,932 4,137,916 Options 1,685,000 — Class A Preferred stock 16,666 16,666 Total potential dilutive effect 43,246,230 4,489,944
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncement to be Adopted In October 2023, 2023 06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Updated and Simplification Initiative" 2023 06 August 2018 not June 30, 2027, not not not In November 2023, No. 2023 07, Segment Reporting (Topic 280 2023 07 280 one December 15, 2023, December 15, 2024. In December 2023, 2023 09, Income Taxes (Topic 740 December 15, 2024.

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	For the Years Ended December 31, 2023 2022 Unvested restricted stock units/awards 98,137 13,137 Common stock issuable 2,101,495 322,225 Warrants 39,344,932 4,137,916 Options 1,685,000 — Class A Preferred stock 16,666 16,666 Total potential dilutive effect 43,246,230 4,489,944

Note 5 - Accounts Payable and_2

Note 5 - Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	As of December 31, 2023 2022 Accounts payable $ 78 $ 129 Accrued employee compensation 11 199 InvaGen contingent fee — 208 Accrued contracted services and other 198 413 Accounts payable and accrued expenses $ 287 $ 949

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]	Number of Units and Awards Weighted Average Grant Date Fair Value Unvested balance at December 31, 2021 94,418 $ 56.25 Forfeited (666 ) 13.95 Vested (80,615 ) 40.83 Unvested balance at December 31, 2022 13,137 $ 12.17 Granted 85,000 1.14 Forfeited — — Vested — — Unvested balance at December 31, 2023 98,137 $ 12.17
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]	For the year ended December 31, 2023 2022 Research and development $ 199 $ 297 General and administrative 707 352 Total stock-based compensation expense $ 906 $ 649
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2021 — $ — $ — Outstanding as of December 31, 2022 — $ — $ — Granted 1,685,000 1.14 Outstanding as of December 31, 2023 1,685,000 $ 1.14 9.50 $ — Vested and Exercisable as of December 31, 2023 262,500 1.14 9.50 $ —
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	For the Year Ended December 31, 2023 2022 Risk-free interest rate 4.14 % — Expected dividend yield — — Expected term in years 5.8 - 5.9 — Expected volatility 125.72 % —
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Weighted Average Exercise Price Aggregate Intrinsic Value (in thousands) Outstanding, December 31, 2021 997 $ 9.98 $ 11 Granted 5,166,119 $ 2.67 — Exercised (1,029,200 ) $ 0.14 — Outstanding, December 31, 2022 4,137,916 $ 1.55 $ 1 Granted 49,479,398 $ 0.26 — Exercised (14,272,382 ) $ 0.00 — Outstanding, December 31, 2023 39,344,932 $ 0.49 $ —

Note 8 - Common Stock Warrant_2

Note 8 - Common Stock Warrant Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	October 2022 January 2023 Warrants Warrants Total Fair value of warrants outstanding as of December 31, 2021 $ - $ — $ — Fair value of warrants at issuance as of October 11, 2022 8,278 — Exercise of warrants (89 ) — Change in fair value of warrants (5,580 ) — Fair value of warrants outstanding as of December 31, 2022 2,609 — 2,609 Fair value of warrants at issuance as of January 31, 2023 — 2,235 Change in fair value of warrants (2,183 ) (2,075 ) Fair value of warrants outstanding as of December 31, 2023 $ 426 $ 160 $ 586
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	December 31, December 31, 2023 2022 (Black-Scholes (Monte Carlo model) Simulation) Stock price $ 0.16 $ 1.16 Risk-free interest rate 3.84 % 4.02 % Expected dividend yield — — Expected term in years 3.78 4.78 Expected volatility 148 % 93 % December 31, January 31, 2023 2023 Stock price $ 0.16 $ 1.38 Risk-free interest rate 4.23 % 3.90 % Expected dividend yield — — Expected term in years 2.10 3.00 Expected volatility 175 % 160 %

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the years ended December 31, 2023 2022 Statutory federal income tax rate 21 % 21 % State taxes, net of federal tax benefit 11 % 10 % State rate change 1 % (1 )% Stock-based compensation 0 % (22 )% Other 0 % 3 % Credits 1 % 4 % None-deductible items (1 )% (11 )% Section 162(m) disallowance 0 % (3 )% Change in fair value of warrant liability 12 % 48 % Change in valuation allowance (45 )% (49 )% Income taxes provision (benefit) 0 % 0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 27,318 $ 25,660 Stock compensation and other 287 42 In process research and development 2,884 1,603 Accruals and reserves 4 64 Business interest expense disallowance — 122 Section 174 capitalization 2,253 622 Tax credits 2,926 2,859 Total deferred tax assets 35,672 30,972 Less valuation allowance (35,672 ) (30,972 ) Deferred tax assets, net of valuation allowance $ — $ —

Note 1 - Organization, Plan o_2

Note 1 - Organization, Plan of Business Operations (Details Textual)									1 Months Ended	12 Months Ended
	Mar. 06, 2024	Nov. 02, 2023 USD ($)	Oct. 31, 2023 $ / shares shares	Sep. 08, 2023 USD ($) $ / shares shares	Jan. 27, 2023 USD ($) $ / shares shares	Oct. 31, 2022 USD ($) $ / shares shares	Sep. 23, 2022 shares	Sep. 30, 2016 shares	Oct. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Jan. 31, 2024 $ / shares shares	Jan. 09, 2024 $ / shares shares	Jan. 05, 2024 $ / shares	Nov. 30, 2023	Feb. 02, 2023 shares	Feb. 01, 2023 shares	Jan. 30, 2023 shares	Jul. 25, 2022 shares	May 11, 2022 USD ($)	Dec. 31, 2021 $ / shares
Common Stock, Shares Authorized (in shares) | shares							20,000,000			75,000,000	20,000,000					75,000,000	20,000,000	55,000,000	50,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 0.01			$ 0.01	$ 0.49	$ 1.55										$ 9.98
Warrants and Rights Outstanding, Term (Year)						5 years			5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares						545,454			545,454
Percentage Of Warrants Issued						15%			15%
Class of Warrant or Right, Exercisable During Period (in shares) | shares						949,900
Class of Warrant or Right, Issued During Period (in shares) | shares						949,900				49,479,398	5,166,119
Stock Issued During Period, Shares, New Issues (in shares) | shares								250,000
Net Proceeds from Issuance Initial Public Offering | $						$ 10.3
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.0001							$ 0.0001	$ 0.0001
Proceeds from Issuance of Private Placement | $				$ 600,000
Retained Earnings (Accumulated Deficit) | $										$ (90,928,000)	$ (80,551,000)
Subsequent Event [Member]
Common Stock, Shares Authorized (in shares) | shares													200,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares													$ 0.0001
January 2023 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 1.55					$ 1.55
Warrants and Rights Outstanding, Term (Year)					3 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares					1,940,299
Class of Warrants or Rights, Offering Price (in dollars per share) | $ / shares					$ 0.125
January 2023 Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares												$ 0.3006
Series A Warrants Associated with November 2023 Public Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.3006
Warrants and Rights Outstanding, Term (Year)			5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares			1
Series A Warrants Associated with November 2023 Public Offering [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares														$ 0.3006
Series B Warrants Associated with November 2023 Public Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.3006
Warrants and Rights Outstanding, Term (Year)			18 months
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares			1
Series B Warrants Associated with November 2023 Public Offering [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares														$ 0.3006
Prefunded Warrant [Member]
Number Of Warrants Issued For A Unit			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.0001
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares			1
Warrants to Certain Investors [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares												$ 0.3006
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares												14,600,000
Units [Member]
Units Issued During Period, Shares, New Issues (in shares) | shares			3,853,400						2,652,065
Number Of Shares Issued For A Unit			1			1
Number Of Warrants Issued For A Unit						1
Units, Price Per Share (in dollars per share) | $ / shares			$ 0.3006			$ 3.3			$ 3.3
Pre Funded Units [Member]
Units Issued During Period, Shares, New Issues (in shares) | shares			12,780,000						984,300
Number Of Shares Issued For A Unit						1
Number Of Warrants Issued For A Unit						1
Number Of Common Shares To Be Purchased For Each Unit						1
Units, Price Per Share (in dollars per share) | $ / shares			$ 0.3005			$ 3.2999			$ 3.2999
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 0.0001			$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares						545,454			545,454
Stock Issued During Period, Shares, New Issues (in shares) | shares						949,900
Securities Purchase Agreement [Member]
Units Issued During Period, Shares, New Issues (in shares) | shares			16,633,400
Stock Issued During Period, Shares, New Issues (in shares) | shares					448,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares					$ 1.55
Prefunded Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 0.001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares					1,492,299
Class of Warrants or Rights, Price Less Than Stock Issuance Price (in dollars per share) | $ / shares					$ 0.001
January 2023 Registered Direct Offering and Private Placement [Member]
Proceeds from Issuance or Sale of Equity | $					$ 2,800,000
Private Placement [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares) | shares				767,085
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares				$ 0.0001
Sale of Stock, Consideration Received on Transaction | $				$ 600,000
Sale of Stock, Price Per Share (in dollars per share) | $ / shares				$ 0.717
November 2023 Public Offering [Member]
Sale of Stock, Cash Transaction Fees, Percentage of Gross Cash Proceeds															8%
Proceeds from Issuance or Sale of Equity | $		$ 3,800,000
Invagen Pharmaceuticals Inc [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares									388,888
Sale of Stock, Cash Transaction Fees, Percentage of Gross Cash Proceeds											7.50%
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $											$ 4,000,000
Payments for Stock Purchase Costs | $										$ 500,000	$ 500,000
Invagen Pharmaceuticals Inc [Member] | General and Administrative Expense [Member]
Business Combination, Consideration Transferred | $									$ 1,900,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio							15
Invagen Pharmaceuticals Inc [Member]
Percentage of Repurchase of Ownership Equity.																				100%
Minimum [Member] | Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	30
Fortress [Member] | Contribution Agreement [Member]
Percentage of Transfer Ownership																				100%
Fortress [Member] | Contribution Agreement [Member] | Minimum [Member]
Gross Proceeds from Equity Financing | $																				$ 7,500,000

Note 2 - Significant Accounti_3

Note 2 - Significant Accounting Policies (Details Textual) $ in Thousands				12 Months Ended
	Jan. 02, 2024 shares	Jan. 01, 2023 shares	Sep. 30, 2016 shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Number of Reportable Segments				1
Number of Operating Segments				1
Stock Issued During Period, Shares, New Issues (in shares)			250,000
Preferred Stock, Dividend Rate, Percentage			2.50%
Common Stock Dividends, Shares (in shares)		231,316
Research And Development Expense, Licenses Acquired | $				$ 300	$ 300
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued | $				$ 0	$ 0
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)				4 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)				10 years
Subsequent Event [Member]
Common Stock Dividends, Shares (in shares)	1,685,767
Common Stock Dividends, Shares, Percentage Of Fully Diluted Outstanding Equity	2.50%

Note 2 - Significant Accounti_4

Note 2 - Significant Accounting Policies - Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive securities (in shares)	43,246,230	4,489,944
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)	98,137	13,137
Common Stock Issuable [Member]
Antidilutive securities (in shares)	2,101,495	322,225
Warrant [Member]
Antidilutive securities (in shares)	39,344,932	4,137,916
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	1,685,000	0
Class A Preferred Shares [Member]
Antidilutive securities (in shares)	16,666	16,666

Note 3 - License Supplier Agr_2

Note 3 - License Supplier Agreement (Details Textual) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended	4 Months Ended	12 Months Ended
	Apr. 27, 2023	Mar. 30, 2023	Feb. 28, 2023	Oct. 29, 2018	Dec. 31, 2019	Jun. 17, 2015	Dec. 31, 2023
Contractual Obligation Development Expense					$ 81,500
Contractual Obligation, Commercial Expense					$ 151,000
Stock Issued During Period, Value, License Expense							$ 1,230
AnnJi [Member]
License Agreement, Purchase Consideration			$ 3,000
Payments to Acquire License	$ 2,000
Acquired License Payable Within 180 Days			1,000
Maximum Reimbursement Amount In Connection With Product Clinical Trial			10,800
Maximum Reimbursement Amount In Connection With Certain Development Milestones			14,500
Maximum Reimbursement Amount In Connection With Certain Drug Development Milestone			27,500
Maximum Reimbursement Amount Upon Achievement of Sales Milestone			$ 165,000
Stock Issued During Period, Shares, License Expense (in shares)		831,618
Stock Issued During Period, Value, License Expense		$ 900
Stock Issuable During Period, Shares, Upon Enrollment of Patient (in shares)			276,652
Stock Issuable During Period, Value, Upon Enrollment of Patient			$ 300
AnnJi [Member] | Minimum [Member]
Sales Milestone Required for Maximum Reimbursement			75,000
Annual Sale Threshold for Royalty Payment			50,000
AnnJi [Member] | Maximum [Member]
Sales Milestone Required for Maximum Reimbursement			750,000
Annual Sale Threshold for Royalty Payment			$ 300,000
Revogenex License [Member]
Contractual Obligation, Maximum Future Payments						$ 3,000
Baergic Licenses [Member] | CCHMC [Member]
Percentage of Equity Fee					5%
Polpharma [Member]
Payments to Acquire in Process Research and Development				$ 2,000
Fortress Biotech Inc [Member] | Iv Tramadol [Member] | Upfront Payment [Member]
Payments to Acquire in Process Research and Development						2,000
Percentage of Equity Fee					20%
Fortress Biotech Inc [Member] | Iv Tramadol [Member] | Additional Payment [Member]
Payments to Acquire in Process Research and Development					$ 1,000	$ 1,000
Baergic Licenses [Member] | Upfront Payment [Member] | CCHMC [Member]
Payments to Acquire in Process Research and Development					200
Baergic Licenses [Member] | Upfront Payment [Member] | AZERBAIJAN
Payments to Acquire in Process Research and Development					$ 3,000
AnnJi [Member]
Right to Sell Common Stock, Price Per Share (in dollars per share)			$ 2.1

Note 4 - Related Party Agreem_2

Note 4 - Related Party Agreements (Details Textual) - USD ($) $ in Thousands				1 Months Ended	12 Months Ended
	Mar. 09, 2017	Sep. 13, 2016	Feb. 17, 2015	Feb. 28, 2015	Dec. 31, 2023	Dec. 31, 2022	Nov. 08, 2022
Fortress [Member]
Notes Assumed				$ 3,000
Percentage of Fully-diluted Outstanding Equity				2.50%
Percentage of Equity or Debt Fnancing				2.50%
Percentage of Annual net Sales				4.50%
Amended Founders Agreements Terms (Year)		15 years
Number Of Shares Exchanged (in shares)		166,027
Fortress [Member] | Management Services Agreement [Member]
Term of Agreement (Year)			5 years
Automatic Renewal Term of Agreement (Year)			5 years
Annual Consulting Fee			$ 500
Increase in Annual Consulting Fee			1,000
Excess in Net Assets Value			$ 100,000
Fortress [Member] | Avenue Baergic Founders Agreement [Member]
Excess in Net Assets Value	$ 100,000
Fortress [Member] | Common Class A [Member]
Number Of Shares Exchanged (in shares)		155,555
Fortress [Member] | Preferred Class A [Member]
Number Of Shares Exchanged (in shares)		250,000
BaergicBio, Inc.[Member]
Proceeds From Equity Fee					$ 23	$ 10
BaergicBio, Inc.[Member] | Founders Agreement and Management Services Agreement [Member]
Percentage of Equity Fee							2.50%
BaergicBio, Inc.[Member] | Avenue Baergic Founders Agreement [Member]
Term of Agreement (Year)	5 years
Annual Consulting Fee	$ 500
Increase in Annual Consulting Fee	$ 1,000
Percentage Of Additional Consideration Of Equity Fee						2.50%
Percentage Considered For The Calculation Of One-Time Fee						4.50%

Note 5 - Accounts Payable and_3

Note 5 - Accounts Payable and Accrued Expenses - Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accounts payable	$ 78	$ 129
Accrued employee compensation	11	199
InvaGen contingent fee	0	208
Accrued contracted services and other	198	413
Nonrelated Party [Member]
Accounts payable and accrued expenses	$ 287	$ 949

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual) $ / shares in Units, $ in Thousands		12 Months Ended
	Jan. 30, 2023 shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Oct. 31, 2023 $ / shares	Feb. 02, 2023 shares	Feb. 01, 2023 shares	Sep. 30, 2022	Sep. 23, 2022 shares	Jul. 25, 2022 shares	Dec. 31, 2021 shares	Sep. 13, 2016 $ / shares shares
Preferred Stock, Shares Authorized (in shares)		2,000,000	2,000,000								2,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares		$ 0.0001	$ 0.0001
Common Stock, Shares Authorized (in shares)	55,000,000	75,000,000	20,000,000		75,000,000	20,000,000		20,000,000	50,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares		$ 0.0001	$ 0.0001	$ 0.0001
Common Stock, Shares, Outstanding (in shares)		25,597,622	4,773,841
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)			80,615
Share-Based Payment Arrangement, Expense | $		$ 906	$ 649
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | $		$ 100	600
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		1 year 7 months 2 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)		3,333
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		10 years
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		1 year 8 months 12 days
Share-Based Payment Arrangement, Expense | $		$ 800	$ 0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $		$ 900
Two Thousand Fifteen Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	5,266,666									266,666
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)		3,352,489
Preferred Class A [Member]
Preferred Stock, Shares Authorized (in shares)											250,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares											$ 0.0001
Preferred Stock, Convertible, Conversion Ratio							15

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Restricted Stock Unit and Award Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Unvested balance (in shares)	13,137	94,418
Unvested balance, Weighted average grant date fair value (in dollars per share)	$ 12.17	$ 56.25
Forfeited (in shares)		(666)
Forfeited, Weighted average grant date fair value (in dollars per share)		$ 13.95
Vested (in shares)		(80,615)
Vested, Weighted average grant date fair value (in dollars per share)		$ 40.83
Granted (in shares)	85,000
Granted, Weighted average grant date fair value (in dollars per share)	$ 1.14
Unvested balance (in shares)	98,137	13,137
Unvested balance, Weighted average grant date fair value (in dollars per share)	$ 12.17	$ 12.17

Note 7 - Stockholders' Equity-

Note 7 - Stockholders' Equity- Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stock-based compensation	$ 906	$ 649
Research and Development Expense [Member]
Stock-based compensation	199	297
General and Administrative Expense [Member]
Stock-based compensation	$ 707	$ 352

Note 7 - Stockholders' Equity_3

Note 7 - Stockholders' Equity - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Outstanding, options (in shares)	1,685,000	0	0
Outstanding, weighted average exercise price (in dollars per share)	$ 1.14	$ 0	$ 0
Outstanding, aggregate intrinsic value	$ 0	$ 0	$ 0
Granted, options (in shares)	1,685,000
Granted, weighted average exercise price (in dollars per share)	$ 1.14
Outstanding, remaining term (Year)	9 years 6 months
Vested and Exercisable as of December 31, 2023 (in shares)	262,500
Vested and Exercisable, weighted average exercise price (in dollars per share)	$ 1.14
Vested and Exercisable, remaining (Year)	9 years 6 months
Vested and Exercisable, aggregate intrinsic value	$ 0

Note 7 - Stockholders' Equity_4

Note 7 - Stockholders' Equity - Estimate Fair Value of Stock Options (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Risk-free interest rate	4.14%	0%
Expected dividend yield	0%	0%
Expected volatility	125.72%	0%
Minimum [Member]
Expected term in years (Year)	5 years 9 months 18 days
Maximum [Member]
Expected term in years (Year)		5 years 10 months 24 days

Note 7 - Stockholders' Equity_5

Note 7 - Stockholders' Equity- Stock Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Oct. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Warrants, outstanding (in shares)		4,137,916	997
Outstanding, weighted average exercise price (in dollars per share)		$ 1.55	$ 9.98
Outstanding, December 31, 2021		$ 1	$ 11
Warrants, Granted (in shares)	949,900	49,479,398	5,166,119
Warrants granted, weighted average exercise price (in dollars per share)		$ 0.26	$ 2.67
Warrants, Exercised (in shares)		(14,272,382)	(1,029,200)
Exercised, weighted average exercise price (in dollars per share)		$ 0	$ 0.14
Warrants granted, weighted average exercise price (in dollars per share)		$ 0.26	$ 2.67
Warrants, outstanding (in shares)		39,344,932	4,137,916
Outstanding, weighted average exercise price (in dollars per share)	$ 0.01	$ 0.49	$ 1.55

Note 8 - Common Stock Warrant_3

Note 8 - Common Stock Warrant Liabilities (Details Textual) - $ / shares	Dec. 31, 2023	Jan. 27, 2023	Dec. 31, 2022	Oct. 31, 2022	Dec. 31, 2021
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.49		$ 1.55	$ 0.01	$ 9.98
January 2023 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.55	$ 1.55

Note 8 - Common Stock Warrant_4

Note 8 - Common Stock Warrant Liabilities - Fair Value of Warrants Liabilities Measured Within Level 3 on Recurring Basis (Details) - Warrant [Member] - Fair Value, Inputs, Level 3 [Member] - Fair Value, Recurring [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Fair value of warrants outstanding	$ 2,609
Fair value of warrants outstanding	586	$ 2,609
October 2022 Warrants [Member]
Fair value of warrants outstanding	2,609	0
Fair value of warrants at issuance		8,278
Exercise of warrants		(89)
Change in fair value of warrants	(2,183)	(5,580)
Fair value of warrants outstanding	426	$ 2,609
January 2023 Warrants [Member]
Fair value of warrants at issuance	2,235
Change in fair value of warrants	(2,075)
Fair value of warrants outstanding	$ 160

Note 8 - Common Stock Warrant_5

Note 8 - Common Stock Warrant Liabilities - Schedule of Warrants under Monte Carlo Simulation and Black-Scholes Model (Details)	Dec. 31, 2023	Jan. 31, 2023	Dec. 31, 2022
Measurement Input, Share Price [Member] | January 2023 Warrants [Member]
Warrant Liability	0.16	1.38
Measurement Input, Share Price [Member] | October 2022 Warrants [Member]
Warrant Liability	0.16		1.16
Measurement Input, Risk Free Interest Rate [Member] | January 2023 Warrants [Member]
Warrant Liability	0.0423	0.039
Measurement Input, Risk Free Interest Rate [Member] | October 2022 Warrants [Member]
Warrant Liability	0.0384		0.0402
Measurement Input, Expected Dividend Rate [Member] | January 2023 Warrants [Member]
Warrant Liability	0	0
Measurement Input, Expected Dividend Rate [Member] | October 2022 Warrants [Member]
Warrant Liability	0		0
Measurement Input, Expected Term [Member] | January 2023 Warrants [Member]
Warrant Liability	2.1	3
Measurement Input, Expected Term [Member] | October 2022 Warrants [Member]
Warrant Liability	3.78		4.78
Measurement Input, Price Volatility [Member] | January 2023 Warrants [Member]
Warrant Liability	1.75	1.60
Measurement Input, Price Volatility [Member] | October 2022 Warrants [Member]
Warrant Liability	1.48		0.93

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Expense (Benefit)	$ 0	$ 0
Deferred Tax Assets, Valuation Allowance	35,672	30,972
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	0	$ 0
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	2,900
Domestic Tax Authority [Member]
Operating Loss Carryforwards	83,900
Domestic Tax Authority [Member] | Indefinite Carryforward [Member]
Operating Loss Carryforwards	69,400
Domestic Tax Authority [Member] | Expires 2034 [Member]
Operating Loss Carryforwards	14,500
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	147,400
State and Local Jurisdiction [Member] | Indefinite Carryforward [Member]
Operating Loss Carryforwards	600
State and Local Jurisdiction [Member] | Expires 2034 [Member]
Operating Loss Carryforwards	$ 146,900

Note 9 - Income Taxes - Reconci

Note 9 - Income Taxes - Reconciliation (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statutory federal income tax rate	21%	21%
State taxes, net of federal tax benefit	11%	10%
State rate change	1%	(1.00%)
Stock-based compensation	0%	(22.00%)
Other	0%	3%
Credits	1%	4%
None-deductible items	(1.00%)	(11.00%)
Section 162(m) disallowance	0%	(3.00%)
Change in fair value of warrant liability	12%	48%
Change in valuation allowance	(45.00%)	(49.00%)
Income taxes provision (benefit)	0%	0%

Note 9 - Income Taxes - Schedul

Note 9 - Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating loss carryforwards	$ 27,318	$ 25,660
Stock compensation and other	287	42
In process research and development	2,884	1,603
Accruals and reserves	4	64
Business interest expense disallowance	0	122
Section 174 capitalization	2,253	622
Tax credits	2,926	2,859
Total deferred tax assets	35,672	30,972
Less valuation allowance	(35,672)	(30,972)
Deferred tax assets, net of valuation allowance	$ 0	$ 0

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details Textual) $ / shares in Units, $ in Millions

Mar. 06, 2024 shares

Jan. 05, 2024 USD ($) $ / shares shares

Nov. 02, 2023 USD ($)

Sep. 23, 2022 shares

Jan. 09, 2024 $ / shares shares

Dec. 31, 2023 $ / shares shares

Nov. 30, 2023 shares

Oct. 31, 2023 $ / shares

Feb. 02, 2023 shares

Feb. 01, 2023 shares

Jan. 30, 2023 shares

Dec. 31, 2022 $ / shares shares

Oct. 31, 2022 $ / shares shares

Jul. 25, 2022 shares

Dec. 31, 2021 $ / shares

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

545,454

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 0.49

$ 1.55

$ 0.01

$ 9.98

Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares

$ 0.0001

$ 0.0001

$ 0.0001

Common Stock, Shares Authorized (in shares) | shares

20,000,000

75,000,000

75,000,000

20,000,000

55,000,000

20,000,000

50,000,000

Reverse Stock Split [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

15

Series A Warrants Associated with November 2023 Public Offering [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

0.3006

Series B Warrants Associated with November 2023 Public Offering [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 0.3006

January 2024 Private Offering [Member] | Series B Warrants Associated with January 2024 Private Offering [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

16,540,299

November 2023 Public Offering [Member]

Proceeds from Issuance or Sale of Equity | $

$ 3.8

November 2023 Public Offering [Member] | Pipe Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

14,600,000

Subsequent Event [Member]

Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares

$ 0.0001

Common Stock, Shares Authorized (in shares) | shares

200,000,000

Subsequent Event [Member] | Reverse Stock Split [Member]

Stock Split, Percent of Holders Signed

56%

Subsequent Event [Member] | Reverse Stock Split [Member] | Series A Preferred Stock [Member]

Number of Stock Held, Signed for Stock Split (in shares) | shares

250,000

Subsequent Event [Member] | Reverse Stock Split [Member] | Common Stock [Member]

Number of Stock Held, Signed for Stock Split (in shares) | shares

3,133,886

Subsequent Event [Member] | Reverse Stock Split [Member] | Minimum [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

30

Subsequent Event [Member] | Reverse Stock Split [Member] | Maximum [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

75

Subsequent Event [Member] | Series A Warrants Associated with November 2023 Public Offering [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 0.3006

Subsequent Event [Member] | Series B Warrants Associated with November 2023 Public Offering [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 0.3006

Subsequent Event [Member] | January 2024 Private Offering [Member]

Proceeds from Issuance or Sale of Equity | $

$ 5

Subsequent Event [Member] | January 2024 Private Offering [Member] | Pipe Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

1,940,299

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 1.55

Subsequent Event [Member] | January 2024 Private Offering [Member] | Series A Warrants Associated with January 2024 Private Offering [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

16,540,299

Subsequent Event [Member] | November 2023 Public Offering [Member]

Sale of Stock, Price Per Unit (in dollars per share) | $ / shares

$ 0.3006